Boji Medical Technology Co.,Ltd.

SZSE:300404 Stock Report

Market Cap: CN¥3.4b

Boji Medical TechnologyLtd Valuation

Is 300404 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 300404 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 300404 (CN¥8.96) is trading above our estimate of fair value (CN¥0.31)

Significantly Below Fair Value: 300404 is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for 300404?

Other financial metrics that can be useful for relative valuation.

300404 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue4.8x
Enterprise Value/EBITDA146.8x
PEG Ratio2.3x

Price to Earnings Ratio vs Peers

How does 300404's PE Ratio compare to its peers?

The above table shows the PE ratio for 300404 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average69.9x
688621 Beijing Sun-Novo Pharmaceutical Research
22.7x28.1%CN¥4.9b
301257 SMO ClinPlusLTD
20.5xn/aCN¥2.6b
301230 PharmaResources (Shanghai)
168x40.2%CN¥3.5b
688131 Shanghai Haoyuan Chemexpress
68.5x41.0%CN¥7.1b
300404 Boji Medical TechnologyLtd
92.3x40.6%CN¥3.4b

Price-To-Earnings vs Peers: 300404 is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the peer average (69.9x).


Price to Earnings Ratio vs Industry

How does 300404's PE Ratio compare vs other companies in the Asian Life Sciences Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a27.1%
n/an/an/a
No more companies

Price-To-Earnings vs Industry: 300404 is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the Asian Life Sciences industry average (29.7x).


Price to Earnings Ratio vs Fair Ratio

What is 300404's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

300404 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio92.3x
Fair PE Ratio36.4x

Price-To-Earnings vs Fair Ratio: 300404 is expensive based on its Price-To-Earnings Ratio (92.3x) compared to the estimated Fair Price-To-Earnings Ratio (36.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies